Cabaletta Bio Nasdaq IPO

16/10/2019

IPO

Value:

$ 87 million

Status:

Announced

Date:

16/10/2019

Overview:

Pennsylvania based autoimmune disease biotech company Cabaletta Bio announced its plans to IPO on Nasdaq.
The company is planning to raise $87 million from offering 5.8 million shares at a range of $14 to $16 per share.

Chynna Lewis – Researcher

Jurisdictions:

United States
New York
Pennsylvania

Deal type:

IPO

Practice area:

Capital markets : Equity

Governing law:

United States

Industry sector:

Pharmaceuticals and life sciences

Firms:

Goodwin Procter

Party: Cabaletta Bio (Issuer)

Lawyers: Michael Minahan, Mitchell Bloom

Ropes & Gray

Party: Morgan Stanley (Bookrunner)

Party: cowen (Bookrunner)

Party: Evercore (Bookrunner)

Related deals